StreetInsider.com News Articles

Form 8-K First Tracks Biotherapeu For: Oct 15

Thu, 15 Oct 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20261015/27193739.html

First Tracks Biotherapeutics raises $200M in private placement

Thu, 15 Oct 2026 08:00:41 -0400

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company, has entered into a securities purchase agreement to sell 6,106,870 shares of common stock to a group of institutional investors in a private placement priced at $32.75 per share.

The company expects to receive approximately $200 million in gross proceeds before placement agent fees and other expenses. Closing is expected to occur on Oct. 19, 2026, subject to customary closing conditions.

Investors participating in the placement include Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, a life sciences-focused institutional investor,

First Tracks Biotherapeutics Announces $200 Million Private Placement

Thu, 15 Oct 2026 08:00:00 -0400

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to

First Tracks Biotherapeutics Announces $200 Million Private Placement

Thu, 15 Oct 2026 08:00:00 -0400

Top biotechnology stock pick from Guggenheim

Wed, 14 Oct 2026 14:32:55 -0400

Investing.com -- Guggenheim has named First Tracks Biotherapeutics TRAX as its top pick in the biotechnology sector following positive data from argenx that builds conviction ahead of TRAX’s fourth quarter 2026 celiac disease data readout.

The investment firm views recent Phase II celiac disease disclosure from argenx as de-risking CD122 biology in celiac disease and providing a positive readthrough for TRAX. Guggenheim’s analysis focuses on four key areas: effect size, study powering, gluten challenge parameters, and expectations for TRAX.

First Tracks Biotherapeutics (TRAX) - Top Pick

Guggenheim maintains First Tracks Biotherapeutics as its top pick following argenx’s positive Phase

Top biotechnology stock pick from Guggenheim

Wed, 14 Oct 2026 14:32:55 -0400

First Tracks Biotherapeutics (TRAX) - Top Pick

Guggenheim maintains First Tracks Biotherapeutics as its top pick following argenx’s positive Phase

Form 8-K First Tracks Biotherapeu For: Oct 12

Tue, 13 Oct 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20261013/27177898.html

First Tracks Biotherapeutics (TRAX) PT Raised to $60 at Canaccord

Tue, 13 Oct 2026 07:17:57 -0400

(Updated - October 13, 2026 7:17 AM EDT)

Canaccord analyst Edward Nash raised the price target on First Tracks Biotherapeutics (NASDAQ: TRAX) to $60.00 (from $50.00) while maintaining a Buy rating.

The analyst commented: "This morning, First Tracks Biotherapeutics announced positive topline data from the Phase Ib trial in celiac disease (CeD). The readout included data from Cohort I, which was designed to assess the ability of ANB033 to prevent mucosal damage induced from gluten challenge. The data reported today were positive and statistically significant on both histological measures like villous height-to-crypt depth ratio (VHCD) and intraepithelial lymphocytes (IEL) density and also

First Tracks Biotherapeutics (TRAX) PT Raised to $60 at Canaccord

Tue, 13 Oct 2026 07:17:57 -0400

(Updated - October 13, 2026 7:17 AM EDT)

Canaccord analyst Edward Nash raised the price target on First Tracks Biotherapeutics (NASDAQ: TRAX) to $60.00 (from $50.00) while maintaining a Buy rating.

First Tracks Biotherapeutics (TRAX) PT Raised to $70 at Wells Fargo

Tue, 13 Oct 2026 06:52:29 -0400

Wells Fargo analyst Derek Archila raised the price target on First Tracks Biotherapeutics (NASDAQ: TRAX) to $70.00 (from $62.00) while maintaining a Overweight rating.

First Tracks Biotherapeutics stock surges 20% on celiac trial data

Mon, 12 Oct 2026 07:27:31 -0400

Investing.com -- First Tracks Biotherapeutics (NASDAQ:TRAX) shares surged 20% Monday after the company announced positive top-line results from its Phase 1b trial evaluating ANB033 in celiac disease.

The study showed ANB033 achieved statistically significant results compared to placebo across key endpoints. The treatment demonstrated a least squares mean change from baseline in villus height-to-crypt depth ratio of -0.17 on ANB033 versus -0.66 on placebo, representing a +0.49 placebo-adjusted delta (p=0.009). For intraepithelial lymphocyte density, ANB033 showed a least squares mean change of -1.20 compared to +18.83 on placebo, a -20.03 placebo-adjusted delta.

The trial evaluated 32 patients in

First Tracks Biotherapeutics stock surges 20% on celiac trial data

Mon, 12 Oct 2026 07:27:31 -0400

Investing.com -- First Tracks Biotherapeutics (NASDAQ:TRAX) shares surged 20% Monday after the company announced positive top-line results from its Phase 1b trial evaluating ANB033 in celiac disease.

The trial evaluated 32 patients in

First Tracks' ANB033 shows positive Phase 1b results in celiac disease

Mon, 12 Oct 2026 07:01:20 -0400

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) reported positive top-line results from Cohort 1 of its Phase 1b trial evaluating ANB033 in celiac disease, according to a company statement released Oct. 12, 2026.

The randomized, placebo-controlled study enrolled 32 patients who completed dosing and a gluten challenge at Week 6. Of those, 17 received ANB033 and 15 received placebo. Patients received three subcutaneous loading doses at Weeks 0, 2, and 4, followed by a 14-day gluten challenge of 6 grams daily — roughly equivalent to two slices of bread.

ANB033 met key histologic endpoints at Week 6. The least squares mean change in

First Tracks' ANB033 shows positive Phase 1b results in celiac disease

Mon, 12 Oct 2026 07:01:20 -0400

ANB033 met key histologic endpoints at Week 6. The least squares mean change in

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

Mon, 12 Oct 2026 07:00:00 -0400

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009)
LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001)
Prevented an increase in symptoms throughout the entire gluten challenge, with lower CDSD score on ANB033 vs. placebo that was statistically significant from the first day
Well tolerated with no safety signals observed to date
Conference call and webcast today, Monday, Oct. 12, 2026, at

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

Mon, 12 Oct 2026 07:00:00 -0400

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009)
LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001)
Prevented an increase in symptoms throughout the entire gluten challenge, with lower CDSD score on ANB033 vs. placebo that was statistically significant from the first day
Well tolerated with no safety signals observed to date
Conference call and webcast today, Monday, Oct. 12, 2026, at

First Tracks Biotherapeutics to release ANB033 celiac trial data Oct. 12

Sun, 11 Oct 2026 16:00:09 -0400

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) announced it will host an investor call and webcast on Oct. 12, 2026, at 8:30 a.m. ET to present top-line data from Cohort 1 of its global Phase 1b trial of ANB033 in celiac disease.

ANB033 is an investigational CD122 antagonist. Cohort 1 is described as a gluten-challenge study designed to assess the prevention of mucosal damage.

According to the company's statement, the data will be released in a morning press release ahead of the webcast presentation. A replay of the webcast will be available for at least 30 days following the event.

In addition to ANB033,

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Sun, 11 Oct 2026 16:00:00 -0400

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.

A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Sun, 11 Oct 2026 16:00:00 -0400

A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The

Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy

Wed, 30 Sep 2026 06:55:06 -0400

(Updated - September 30, 2026 6:55 AM EDT)

Canaccord analyst Edward Nash initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $50.00.

The analyst comments "We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12- month price target of $50. The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis

Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy

Wed, 30 Sep 2026 06:55:06 -0400

(Updated - September 30, 2026 6:55 AM EDT)

Canaccord analyst Edward Nash initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $50.00.

Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform

Fri, 18 Sep 2026 06:06:30 -0400

Evercore ISI initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Outperform rating and a price target of $65.00.

For an analyst ratings summary and ratings history on First Tracks Biotherapeutics click here. For more ratings news on First Tracks Biotherapeutics click here.

Shares of First Tracks Biotherapeutics closed at $39.20 yesterday.

Form 4 First Tracks Biotherapeu For: Sep 15 Filed by: Orwin John A

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075837.html

Form 4 First Tracks Biotherapeu For: Sep 15 Filed by: Orwin John A

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075837.html

This biotech stock is a new Top Pick at Guggenheim

Thu, 17 Sep 2026 14:00:00 -0400

Guggenheim named a biotech name as a new top pick in a note on Thursday, initiating coverage with a Buy rating and $100 price target.

The stock in question is First Tracks Biotherapeutics (NASDAQ: TRAX). The firm's thesis centers on high conviction in the anti-CD122 target and lead asset ANB033, which it sees having potential across multiple autoimmune diseases.

Guggenheim said it flagged CD122/IL-15 as "one of immunology's most consequential undeveloped targets" back in January 2025 and has since seen substantial clinical progress.

"TRAX is a new Top Pick," the firm wrote, noting First Tracks is the only publicly traded small- or